Search the Newsreel

Xenon Pharmaceuticals Independent Director Steven Gannon Sells 84% Of Holding

Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts

Industry analysts have significantly upgraded their revenue forecasts for Xencor, Inc. (NASDAQ:XNCR) for 2026, with the consensus estimate now at US$144 million, a 37% increase from the previous year's sales. This revised outlook suggests a much more bullish perspective on the company's prospects, forecasting …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

Crexendo Surpasses 8 Million Users as Global Adoption of Its Cloud Communications Platform Accelerates

Crexendo, Inc. announced that its AI-enhanced UCaaS software platform now supports over 8 million users worldwide, marking a significant milestone. The company has added approximately one million users in the past eight months, and its user base has grown by over 370% since the …

Toscafund group discloses 4.3% Nexxen International (NEXN) holding in 13G/A

Toscafund Asset Management LLP, Toscafund Limited, Old Oaks Holdings Limited, and Martin Hughes have filed an amended Schedule 13G/A, revealing a collective beneficial ownership of 2,403,533 ordinary shares in Nexxen International Ltd. (NEXN), which represents 4.3% of the class. The group has shared voting …

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from seventeen brokerages, with an average 12-month price target of $77.13. The company's stock is currently trading below its recent high, with institutional investors holding a significant 95.45% stake. Recent insider selling has also …

CXDO insider plans 30,000-share sale in Nasdaq: CXDO Form 144 filing

David Wang, an insider at Crexendo, Inc. (CXDO), has filed a Form 144 to sell up to 30,000 shares of common stock through Wells Fargo Clearing Services, LLC, with an aggregate market value of $210,000. The filing also indicates Wang's current ownership of 193,366 …

Nexxen (NEXN) Stock Sees CTV Strength Collide With Profit Pressure

Nexxen International (NEXN) posted strong Q2 results with record programmatic revenue and raised full-year guidance, driven by growth in CTV and data products. Despite these gains, net income and EPS declined, leading to concerns about profitability amidst increased operating costs and investment intensity. The …

Xenon Pharmaceuticals Director Sold Shares Worth Over $640K

Steven Gannon, a Director at Xenon Pharmaceuticals (XENE), reported the sale of common shares totaling $640,550 on August 11, 2026. The transactions were executed at a weighted-average price of $64.055 per share. Following this sale, Gannon directly holds 1,870 common shares in the company.

(XNCR) as a Liquidity Pulse for Institutional Tactics

This article analyzes Xencor Inc. (NASDAQ: XNCR) based on AI models, identifying strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored …

(XHR) Volatility Zones as Tactical Triggers

Xenia Hotels & Resorts Inc. (NYSE: XHR) is exhibiting weak near and mid-term sentiment, potentially challenging its long-term positive outlook. The stock is testing resistance, with models suggesting a potential short setup offering a 28.8:1 risk-reward ratio targeting a 9.0% downside. Institutional trading strategies …

Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct

Director Steven Gannon of Xenon Pharmaceuticals (XENE) sold 10,000 shares for $64.06 per share, totaling $640,600, reducing his direct holdings to 1,870 shares. This sale contributes to a broader trend of 13 insider sells and no buys over the past year at Xenon, signaling …

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients

Wellington Management Group LLP and its affiliates have reported a passive ownership stake of approximately 1.47% in Xenon Pharmaceuticals Inc. (XENE) common stock. This stake, representing 1,425,492 shares, is held for advisory clients across various Wellington investment entities, with no single client owning more …

Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64

Xenon Pharmaceuticals director Steven Gannon sold 10,000 Common Shares on August 11, 2026, at a weighted-average price of $64.055 per share. The shares were sold in multiple transactions ranging from $64.0517 to $64.078. Following this transaction, Gannon directly holds 1,870 Common Shares of Xenon …

Wellington entities report 4.42% Xenia Hotels (XHR) stake held for clients

Wellington Management Group LLP and its related entities have reported a 4.42% beneficial ownership stake in Xenia Hotels & Resorts, Inc. (XHR) as of June 30, 2026. This stake, totaling 4,081,029 shares, is held for their investment advisory clients, with shared voting power over …

Nexxen International (NEXN) Stock Fair Value Edges Higher As Analysts Lift Targets

Analysts have increased their price targets for Nexxen International (NEXN), leading to an updated fair value for the stock of US$12.99, up from US$12.19. This revision is driven by strong Q2 results, increased exposure to connected TV, mobile in-app, and enterprise clients, and investments …

Xenia Hotels & Resorts (XHR) Is Down 8.1% After Equity Raise And Guidance Cut Has The Bull Case Changed?

Xenia Hotels & Resorts (XHR) recently completed a US$136.91 million equity offering and simultaneously cut its full-year 2026 earnings guidance, leading to an 8.1% stock drop. This move shifts the company's focus from share repurchases to balance sheet reinforcement amidst macroeconomic uncertainty. The new …

Canaccord Genuity Group Issues Positive Forecast for Nexxen International (NASDAQ:NEXN) Stock Price

Scotiabank Forecasts Strong Price Appreciation for Nexxen International (NASDAQ:NEXN) Stock

Scotiabank raised its price target for Nexxen International (NASDAQ:NEXN) to $13 from $11, maintaining a "sector outperform" rating and indicating a potential upside of 23.81%. This upgrade follows Nexxen's strong quarterly results, where EPS and revenue exceeded analyst expectations. Despite a slight dip in …

Nexxen International (NASDAQ:NEXN) Sets New 52-Week High Following Earnings Beat

NEXN Maintained by Rosenblatt -- Price Target Stays at $16.00

Canaccord raises Nexxen stock price target on CTV recovery momentum

Canaccord has increased its price target for Nexxen (NASDAQ:NEXN) to $13 from $11, maintaining a Buy rating, following the company's strong second-quarter results which exceeded consensus expectations. Nexxen's performance was driven by a robust recovery in connected TV, expanded enterprise customer spending, and growth …

Nexxen International DRC earnings beat by $0.03, revenue topped estimates

Nexxen International Ltd. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NEXN) 2026-08-12

Nexxen International (NEXN) reported record second-quarter results, driven by strong growth in connected television, mobile, and data products. The company exceeded consensus estimates and raised its full-year outlook for contribution ex-TAC and programmatic revenue, attributing success to investments in its integrated platform, AI capabilities, …

NEXN Stock Price and Chart — NASDAQ:NEXN

This article provides a detailed overview of Nexxen International Ltd. (NEXN) stock, including its current price, market capitalization, financial performance, and analyst ratings. It highlights key statistics such as revenue and EPS, recent earnings reports, and future forecasts, along with a list of ETFs …

Nexxen International (NASDAQ:NEXN) Price Target Raised to $13.00 at Needham & Company LLC

Needham & Company LLC has increased its price target for Nexxen International (NASDAQ:NEXN) to $13.00 from $10.50, maintaining a "buy" rating and indicating a potential upside of 24.05%. This follows Nexxen exceeding its Q2 earnings and revenue expectations, with the company reporting $0.23 EPS …

Nexxen International (NASDAQ:NEXN) Issues Quarterly Earnings Results

Nexxen International Q2 Earnings Call Highlights

Key Points Interested in Nexxen International Ltd. Sponsored ADR? Here are five stocks we like better. Record Q2 performance: Contribution ex-TAC rose 11% year over year to $97.8 million, while programmatic revenue increased 12% to $95.2 million. CTV revenue jumped 33% to a record …

Earnings call transcript: Nexxen lifts 2026 outlook after record Q2 growth

Nexxen International Ltd. reported record second-quarter results with double-digit growth in contribution ex-TAC and programmatic revenue, leading management to raise its full-year 2026 revenue guidance for the third time this year. Despite a slight dip in non-IFRS diluted earnings per share due to increased …

Nexxen International Ltd reports results for the quarter ended June 30 - Earnings Summary

Nexxen International Ltd has reported its financial results for the quarter that ended on June 30. This brief summary indicates the availability of the earnings report. The full article content is behind a paywall, requiring a subscription to TradingView to access.

Nexxen International (NASDAQ: NEXN) lifts 2026 outlook after record Q2 CTV growth

Three Nexxen Executives Take New Roles Across Its Ad Platform

Nexxen (NASDAQ: NEXN) has announced key executive appointments to drive the next phase of growth for its unified, AI-driven advertising platform. Chance Johnson is now President, Kara Puccinelli is Chief Commercial Officer, and Kenneth Suh is Chief Business Officer. These changes aim to strengthen …